RE:RE:RE:Financing By the way, I'm always quoting USD prices, as is the norm for the company's accounting. Not sure if it's the same for this board. Pricing of a secondary at $2 USD even after positive news does not seem outlandish if market participants decide to take advantage of the current lack of interest for the stock to walk it down as far as possible.
longterm56 wrote: Hmm ... if I do the math, to raise 20M with a dilution of 12% means you sell 9,240,000 shares @ $2.16/sh ???? Where do I sign up!!!!
-LT
Spartrap wrote: I think the same as you, a probable (healthy) raise of 15-20M, capped by a maximum dilution of 12%.
This will be a major test for the competence/ business acumen of management, as a well conducted raise can be majorly bullish, but when it's done by amateurs, it can be a failure of epic proportions, as I have unfortunalely experienced in the past.
palinc2000 wrote: There is no doubt in my mind that they will need to get cash to fund the upcoming clinical trials in both Nash and Oncology
The market knows that cash is needed.
There are not too many options
-1- Share Offering by way of an ATM at their own choosing
2- Share Offering at the then prevailing share price
Hopefully the SP will go up before 1or 2 but they wont hesitate to dilute at whatever price if no other options available
3- Out licensing or partnering(Nash or Oncology)
How much will they want to raise ? Maybe atound 15-20 million maybe.a bit less
I dont think anything will happen on the Financing front before FDA approves the Phase 3 protocol .....but the market knows that $$$$$ are needed
Once the Financing is settled coupled with FDA approval and maybe positive surprises on the Sales front we can start the climb to double digit SP maybe by year end